Doms № 1 -2022

Doms № 1 -2022 (54-63 p)

Diabetic kidney disease
Sakharova Yu. V. – 54-63


Diabetes mellitus is a chronic, incurable disease that requires constant treatment for a long time. Despite the existing successes in the treatment of diabetes, there is an increase in morbidity in both type 1 and type 2 diabetes mellitus. According to the forecasts, by 2040 the number of people suffering from diabetes at the age of 20–79 will increase to 642 million. However, despite the present successes to over 100 years since the development of the first methods of treating diabetes, this disease not only remains one of the biggest problems in the world, but it is becoming more and more widespreading, taking on a character of pandemic. The greatest danger of diabetes mellitus is associated with complications that are characterized by damage both the peripheral nervous system and damage to blood vessels, in particular, with the development of a formidable complex as diabetic nephropathy, which develops in 30–40 % of patients with type 1 and type 2 diabetes and takes a leading position among the causes of chronic kidney failure worldwide. In patients with type 2 diabetes diabetic nephropathy ranks third among the causes of death after cardiovascular system diseases and oncological pathologies. Constant expansion of knowledge about the mechanisms of action of damage to vessels, and in particular, renal pathology in diabetes has an important role in the prognosis of the disease and treatment of its complications. This is a review article about the diabetes kidney disease.

Keywords: Diabetes mellitus type 1, diabetes mellitus type 2, diabetes kidney disease, diabetic nephropathy, complications.


  1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Di- abetes Atlas: Global estimatesfor the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50.
  2. Shestakova MV, Shamhalova MSh, Iarek-Marty`nova IIA i dr. Saharny`i` diabet i khronicheskaia bolezn` pochek: dostizheniia, nereshenny`e problemy` i perspektivy` lech- eniia. Saharny`i` diabet 2011; 1: 81-88
  3. Reutens A.T. Epidemiology of diabetic kidney disease. Med Clin North Am. 2013; 97(1): 1– (In Australia.)
  4. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in Patients with Type 2 Diabetes. N Engl J Med. 2002; 346(15): 1145- 1151.
  5. Granier C, Makni K, Molina L et al. Gene and protein markers of diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 7922-8799
  6. Otu HH, Can H, Spentzos D, et al. Prediction of diabet- ic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care. 2007;30(3):638– doi: 10.2337/dc06-1656
  7. Сахарный диабет: диагностика, лечение, профилактика / Под ред. И.И. Дедова, М.В. Шестаковой. М.: Медицинское информационное агентство; 2011.
  8. Лебедева Н.О., Викулова O.K. Маркеры доклинической диагностики диабетической нефропатии у пациентов с сахарным диабетом 1 типа. Сахарный диабет. 2012; 2: 38–45.
  9. Gu H.F., Brismar K. Genetic association studies in diabetic nephropathy. Curr. Diabet. Rev. 2012; 8 (5): 336–44.
  10. Araki S. APOE polymorphism and diabetic nephropathy.Exp. Nephrol. 2014; 18 (2): 230–3.
  11. Rizvi S., Raza S.T., Mahdi F. Association of genetic vari-ants with diabetic nephropathy. World J. Diabet. 2014; 5(6): 809–16.
  12. K.,SinghU.K.Molecularmechanismsinthepatho-genesis of diabetic nephropathy: an update. Vasc. Pharmacol2013; 58 (4): 259–71.
  13. Dronavalli S., Duka I., Bakris G.L. The pathogenesis of dia-betic nephropathy. Nature Clin. Pract. Endocrinol. Metab.2008; 4 (8): 444–52.
  14. Horvat S., Jakas A. Peptide and amino acid glycation: newinsights into the Maillard reaction. J. Pept. Sci. 2004; 10(3): 119–37.
  15. Thorpe S.R., Baynes J.W. Maillard reaction products in tissueproteins: new products and new perspectives. Amino Acids.2003; 25 (3–4): 275–81.
  16. Singh R., Barden A., Mori T., Beilin L. Advanced glycationendproducts: a review. Diabetologia. 2001; 44 (2): 129–46.
  17. Hidalgo F.J., Zamora R. Interplay between the maillard reaction and lipid peroxidation in biochemical systems. Ann. N.Acad. Sci. 2005; 1043: 319–26
  18. Robinson T.W., Freedman B.I. Assessing glycemic controlin diabetic patients with severe nephropathy. J. Ren. Nutr.2013; 23 (3): 199–202.
  19. Twig G., Afek A., Derazne E., Tzur D., Cukierman-Yaffe T.,Gerstein H.C., Tirosh A. Diabetes risk among overweight and obese metabolically healthy young adults. Diabet. Care. 2014; 37 (11): 2989–95.
  20. Satirapoj B. Nephropathy in diabetes. Adv. Exp. Med. Biol. 2012; 771: 107–22.

  21. Brosius F.C., Pennathur S. How to find a prognostic bio- marker for progressive diabetic nephropathy. Kidney Int. 2013; 83 (6): 996–8.
  22. Fedorova EY, Kutyrina IM. Mechanisms of progression of kidney injury in obesity. Review. Nephrology and dialysis. 2006; 8(2): 102_111.
  1. Vyalkova AA, Lebedeva EN, Krasikov SI, Zorin IV, Kulagina EP, Nikolaeva SN. Clinical and paphogenical aspects of kidney damage in obesity (review). Nephrology (Saint_Pe- tersburg). 2014; 18(3): 24_33.

  2. Kovesdy CP, Furth S, Zoccali C. Obesity and kidney disease: hidden consequences of the epidemic. Clinical nephrology. 2017; (1): 3_11.
  3. Nanayakkara PW, Le Poole CY, Fouque D, van Guldener C, Stehouwer CD, Smulders YM et al. Plasma adiponectin concentration has an in verse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3_5 chronic kidney disease. Clin. Nephrol. 2009; 72(1): 21_30.
  4. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006; 17(4 Suppl 2): S81_S85. DOI: 10.1681/ASN.2005121332
  5. Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes. 2006; 55(9): 2502_2509. DOI: 10.2337/ db05_0603
  6. Shankar SS, Steinberg HO. FFAs: Do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep. 2005; 5(1): 30_35.
  7. ThomasME,HarrisKP,WallsJ,FurnessPN,Brunskill NJ. Fatty acids exacerbate tubulointerstitial injury in protein_overloaded proteinuria. Am J Physiol Renal Physiol. 2002; 283(4): F640_F647.
  8. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS et al. Modulation of blood pressure by central melanocortinergic pathways. NEJM. 2009; 360(1): 44_52. DOI: 10.1056/NEJMoa0803085
  9. Gu H.F., Brismar K. Genetic association studies in diabetic nephropathy. Curr. Diabet. Rev. 2012; 8 (5): 336–44.
  10. Rizvi S., Raza S.T., Mahdi F. Association of genetic variants with diabetic nephropathy. World J. Diabet. 2014; 5(6): 809–16.
  11. Macisaac R.J., Ekinci E.I., Jerums G. Markers of and risk factors for the development and progression of diabetickidney disease. Am. J. Kidney Dis. 2014; 63 (Suppl. 2): 39–62.
  12. Jeon Y.L., Kim M.H., Lee W.I., Kang S.Y. Cystatin C as an early marker of diabetic nephropathy in patients with type2 diabetes. Clin. Lab. 2013; 59 (11–12): 1221–9.
  13. You H., Gao T., Cooper T.K., Brian Reeves W., Awad A.S. Macrophages directly mediate diabetic renal injury. Am. J.Renal. Physiol. 2013; 305 (12): 1719–27.
  14. Kimmelstiel P, Wilson C. Intercapillary lesion in the glomeruli of the kidney. Am J Pathol 1936; 12: 82-97
  15. Stitt-Cavanagh E, MacLeod L, Kennedy CRJ. The podocyte in diabetic kidney disease. The Scientific World Journal2009; 9:1127-1139
  16. Reddy GR, Kotlyarevska K, Ransom RF. The podocyte and diabetes mellitus: is the podocyte key to the origins of diabetic nephropathy? Сurr Opin Nephrol Hypertens 2008; 17: 32-36
  17. Wolf G, Chen S, Ziyadeh FN. From the periphery of glomerular capillary wall toward the center of disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54(6): 1626-1634
  18. Ziyadeh FN, Wolf G. Pathogenesis of podocytopathy and proteiuria in diabetic glomerulopathy. Current Diabetes Reviews 2008; 4: 39-45
  19. Steffes MW, Schmidt D, McGregory R, Basgen JM. Glomerular cell number in normal subject and in type 1diabetic patients. Kidney Int 2001; 59: 2104-2113
  20. Lewko B, Stepinski J. Hypergliycemia and mechanical stress: Targeting the renal podocyte. J Cell Physiol 2009; 221(2): 288-295
  21. Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis 2011; 58(4): 637-646
  22. Tervaert T.W., Mooyaart A.L., Amann K., Cohen A.H., Cook H.T., Drachenberg C.B. et al. Renal Pathology Society. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 2010; 21 (4): 556–63.
  23. Demirel F., Tepe D., Kara O., Esen I. Microvascular compli- cations in adolescents with type 1 diabetes mellitus. J. Clin. Res. Pediatr. Endocrinol. 2013; 5 (3): 145–9.
  24. Zakhar’ina O.A., Tarasov A.A., Babaeva A.R. Current aspects of drug prevention and treatment of diabetic angiopathy. Lekarstvennyy vestnik. 2012; 6 (5): 14– (in Russian)
    Ziyadeh F.N., Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabet. Rev. 2008; 4 (1): 39–45.
  25. Li J.J., Kwak S.J., Jung D.S., Kim J.J., Yoo T.H., Ryu D.R. et al. Podocyte biology in diabetic nephropathy. Kidney Int. 2007; Suppl. 106: S36–42.
  26. Wolf G., Ziyadeh F.N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol. 2007; 106 (2): 26–31.
  27. Chen S., Jim B., Ziyadeh F.N. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin. Nephrol. 2003; 23 (6): 532–43.
  28. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL . Kidney Int. 2004; 65 (6): 2309–20.
  29. You H., Gao T., Cooper T.K., Brian Reeves W., Awad A.S. Macrophages directly mediate diabetic renal injury. Am. J. Physiol. Renal. Physiol. 2013; 305 (12): 1719–27
  30. W.,MooyaartA.L.,AmannK.,CohenA.H., Cook H.T., Drachenberg C.B. et al. Renal Pathology Society. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 2010; 21 (4): 556–63.
  31. Cherney D.Z., Scholey J.W., Daneman D., Dunger D.B., Dalton R.N., Moineddin R. et al. Urinary markers of renal in- flammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria. Diabet. Med. 2012; 29 (10): 1297–302.
  32. Har R., Scholey J.W., Daneman D., Mahmud F.H., Dekker R., Lai V. et al. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with un- complicated type 1 diabetes mellitus. Diabetologia. 2013; 56 (5): 1166–73.
  33. Prunotto M., Ghiggeri G., Bruschi M., Gabbiani G., Lescuyer P., Hocher B. et al. Renal fibrosis and proteomics: current knowledge and still key open questions for proteomic inves- tigation. J. Proteomics. 2011; 74 (10): 1855–70.
  34. McMahon G.M., Waikar S.S. Biomarkers in nephrology: Core Curriculum 2013. Am. J. Kidney Dis. 2013; 62 (1): 165–78.
  35. Yokoyama H., Deckert T. Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet. Med. 1996; 13 (4): 313–20.
  36. Eleftheriadis T., Antoniadi G., Pissas G., Liakopoulos V., Stefanidis The renal endothelium in diabetic nephropathy. Ren. Fail. 2013; 35 (4): 592–9.
  37. Joshi M.S., Berger P.J., Kaye D.M., Pearson J.T., Bauer J.A., Ritchie R.H. Functional relevance of genetic variations of endothelial nitric oxide synthase and vascular endothelial growth factor in diabetic coronary microvessel dysfunction. Clin. Exp. Pharmacol. Physiol. 2013; 40 (4): 253–61.
  38. Gohda T., Tomino Y. Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors. Curr. Diabet. Rep. 2013; 13 (4): 560–6.
  39. Смирнов И.Е., Герасимова Н.П., Комарова Н.Л., Видюков В.И. Новый способ определения объема функциональной активной ткани почек у детей. Российский педиатрический журнал. 2011; 2: 48–51.


    Received: 02.12.2021

    Revised: 25.01.2022

    Accepted: 15.01.2022